Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese Relapsing Multiple Sclerosis Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
Condition: Multiple Sclerosis Intervention: Drug: TERIFLUNOMIDE Sponsor: Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials